Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

81.71 -0.11 (-0.13%)
Official Closing Price Updated: 7:00 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025
The Dow Jones index could have fared better in May if not for these two stocks. 
Via The Motley Fool
Topics Government Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery
Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial. 
Via Benzinga
Exposures Product Safety
Merck Gets FDA Approval For Keytruda To Treat A Broader Population Of Head And Neck Cancer Patients: Retail Stays Bullish
In the U.S., it is estimated there will be approximately 72,680 new cases of head and neck cancer diagnosed and more than 16,680 deaths from the disease in 2025, Merck said. 
Via Stocktwits
Topics Death
Exposures Death Product Safety
FDA Approves KEYTRUDA® (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as a Single Agent
From Merck & Co., Inc.
Via Business Wire
Price Over Earnings Overview: Merck & Co
Via Benzinga
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
From Merck & Co., Inc.
Via Business Wire
RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit
Martin Kulldorff, appointed by RFK Jr. to a federal vaccine panel, previously earned $33K as an expert witness in lawsuits targeting Merck's Gardasil vaccine. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
From Merck & Co., Inc.
Via Business Wire
Unpacking the Latest Options Trading Trends in Merck & Co
Via Benzinga
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility
Via The Motley Fool
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Unpacking the Latest Options Trading Trends in Merck & Co
Via Benzinga
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Pick in Pharmaceuticals
MERCK & CO. INC. (NYSE:MRK) is a value stock with strong profitability, a healthy balance sheet, and an attractive dividend. Trading below industry valuations, it may appeal to long-term investors. 
Via Chartmill
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
From Merck & Co., Inc.
Via Business Wire
Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials
Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety concerns reported. 
Via Benzinga
Merck Announces Positive Data From Trials For Cholesterol Drug, But Retail Reaction Is Sluggish
Dean Y. Li, president of Merck Research Laboratories, said that the company is working with urgency to make the oral therapy available to patients worldwide. 
Via Stocktwits
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Top S&P500 movers in Monday's pre-market session
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses. 
Via Chartmill
Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia
From Merck & Co., Inc.
Via Business Wire
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Each of the index's highest-yielding names has its own unique story right now. 
Via The Motley Fool
Topics Economy Stocks
Exposures Interest Rates US Equities
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta
Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates. 
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives. 
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
1 Value Stock to Target This Week and 2 to Question
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover
The deal is being discussed ahead of key data from MoonLake in patients with a skin disease. 
Via Investor's Business Daily
Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report
Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it faces revenue pressure from Keytruda's looming patent cliff. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.